Academic Journal
Q1Cancer Biology and Medicine
About Cancer Biology and Medicine
Cancer Biology and Medicine is a scholarly journal published by Cancer Biology and Medicine. SCImago 2025 lists it in Q1, with an SJR of 1.888 and H-index of 78.
Coverage: 2012-2026. Research categories: Cancer Research (Q1); Oncology (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2024-04-11. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Cancer Immunotherapy and Biomarkers; Immunotherapy and Immune Responses; Cancer Genomics and Diagnostics; Lung Cancer Treatments and Mutations; Ferroptosis and cancer prognosis; Immune cells in cancer.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
A bispecific EGFR × HER3 antibody–drug conjugate for later-line recurrent or metastatic nasopharyngeal carcinoma: insights from BL-B01D1-303
Huaqiang Zhou, Jiayi Shen, Jiaqing Liu, Li Zhang et al.
2026-09-23 · DOI: 10.20892/j.issn.2095-3941.2026.0336Efbemalenograstim alfa as prophylaxis for chemotherapy-induced neutropenia in patients with non–small-cell lung cancer: a randomized, multicenter, phase II trial
Mengjie Li, Caixia Liu, Fengming Ran, Haitao Lan et al.
2026-09-17 · DOI: 10.20892/j.issn.2095-3941.2026.0311Revisiting the immunosuppressive microenvironment in hepatocellular carcinoma: a functional taxonomy of immune cells and therapeutic targeting
Jiaqian Zhang, Siwen Li, Xianglong Ma, Xiaomin You et al.
2026-09-15 · DOI: 10.20892/j.issn.2095-3941.2026.0154Erratum to From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management
Junnan Xu, Kun Fang, Xiaoxi Li, Li Han et al.
2026-09-08 · DOI: 10.20892/j.issn.2095-3941.2026.0704Migrasome-propagated ITGβ3-TGFβ1 circuit orchestrates breast cancer brain metastasis by reprogramming the microglial niche
Song Wang, Xinmiao Xian, Guohao Gu, Jianran Guo et al.
2026-09-08 · DOI: 10.20892/j.issn.2095-3941.2025.0803cGAS–STING pathway activation drives the cold-to-hot tumor transition and sensitizes immunotherapy
Xinru Zhao, Shuai Meng, Hanzeng Cheng, Haixia Yu et al.
2026-08-13 · DOI: 10.20892/j.issn.2095-3941.2026.0058Rethinking nasopharyngeal carcinoma management: toward a low-toxicity, highly effective regimen with favorable tolerability and quality of life
Yingni Zhang, Chunxian Ou, Cheng Xu
2026-08-08 · DOI: 10.20892/j.issn.2095-3941.2026.0316Global landscape and temporal trends in lifetime risk of colorectal cancer in 185 countries: a population-based study
Li Li, Kexin Sun, Xiang Li, Yifei Yao et al.
2026-08-06 · DOI: 10.20892/j.issn.2095-3941.2025.0851Anogenital human papillomavirus infection patterns by anatomical site and sexual orientation in Chinese men: a national multi-center study
Shangying Hu, Huan Yang, Jinyu Zhang, Hongyang Yu et al.
2026-08-04 · DOI: 10.20892/j.issn.2095-3941.2026.0129FDX1 expression promotes DSF/Cu-induced cuproptosis in gastric cancer cells
Qirong Li, Yi Guo, Jiahuan Yuan, Qiang Feng et al.
2026-07-28 · DOI: 10.20892/j.issn.2095-3941.2025.0323Myeloid cell reprogramming combined with zoledronic acid effectively suppresses bone metastasis
Yuting Luo, Yiran Cai, Zizheng Jiang, Ke Zheng et al.
2026-07-27 · DOI: 10.20892/j.issn.2095-3941.2026.0168From chemical compounds to herbal interventions: a transfer learning-based perturbational transcriptome prediction framework for cancer drug discovery
Qingyuan Liu, Boyang Wang, Shao Li
2026-07-22 · DOI: 10.20892/j.issn.2095-3941.2026.0032Global patterns, temporal trends and socioeconomic inequalities in the burden of breast cancer: a population-based study across 185 countries
Weijia Kong, Hengna Lin, Jie Li, Yaxiong Nie et al.
2026-07-21 · DOI: 10.20892/j.issn.2095-3941.2026.0059Harnessing the microbiome: a new frontier in lung cancer immunotherapy
Kexin Feng, Jun Wang, Shuai Wang, Zewen Sun et al.
2026-07-20 · DOI: 10.20892/j.issn.2095-3941.2025.0177Next-generation CAR immunotherapy for neuroblastoma: expanding the role of immune cell platforms
Ke-En Tan, Kok Siong Yeo, Yat-Yuen Lim, Shizhen Zhu et al.
2026-07-20 · DOI: 10.20892/j.issn.2095-3941.2026.0155Apatinib enhances targeted immunotherapy <italic>via</italic> the IL-6-gp130-PI3K pathway in HER2-positive gastric cancer
Ruoxi Tian, Ziyue Sha, Shasha Zhang, Miao Gong et al.
2026-07-20 · DOI: 10.20892/j.issn.2095-3941.2025.0687Genetic susceptibility, environmental risk factors, and incident gastric cancer risk among individuals with different Helicobacter pylori infection status: a population-based study
Hengmin Xu, Hui Ma, Yuxin Wang, Xinling Wang et al.
2026-07-14 · DOI: 10.20892/j.issn.2095-3941.2026.0145Vitamin D potentiates STING agonist-induced antitumor immunity in NSCLC
Ke Li, Guichao Liu, Wenhui Yuan, Xinhai Zhu et al.
2026-07-13 · DOI: 10.20892/j.issn.2095-3941.2026.0211The conditional promise of dual-epitope HER2 antibody-drug conjugates in breast cancer
Ruoqing Wang, Shuhao Jiang, Qun Zhang, Junjie Li et al.
2026-07-13 · DOI: 10.20892/j.issn.2095-3941.2026.0277Dietary restriction during active cancer therapy is associated with improved treatment response: a systematic review and meta-analysis
Kajal Agrawal, Dominic Shao Yong Goh, Ee Chern Ng, Shyn Yi Tan et al.
2026-07-13 · DOI: 10.20892/j.issn.2095-3941.2025.0841Reviews
Community Reviews
Version History
October 4, 2026 at 8:48 pm
September 25, 2026